Office Action 2: Notice of Allowance (2025-02-21)

CLAIMS:
We claim:
1. An elongated hexagonal decorative light system comprising:
a plurality of light panel assemblies, each light panel assembly further comprising:
a base having an elongate hexagonal shaped outer periphery, the base defining two connector apertures at each end of the elongate base in a bottom of the base;
a printed circuit assembly mounted to the base and having a first plurality of white light emitting diodes populated thereon and a second plurality of colored light emitting diodes populated thereon and electronic circuitry for selectively illuminating between the white light emitting diodes and the colored light emitting diodes and further including logic to illuminate the light emitting diodes thereon in a plurality of predetermined patterns and light motions;
a plurality of electrical receptacles, at least two receptacles positioned at each end of the printed circuit assembly, each electrical receptacle in registration with one of the connector apertures defined in the base at each end of the elongate base; and
a prismatically shaped lens affixed to an upper surface of the base;
a controller having a base receiving an electrical power cord, the power cord electrically connected to a printed circuit assembly mounted on the base wherein the printed circuit assembly includes the circuitry and logic for controlling the plurality of light panel assemblies, and the controller further terminating with an electrical connector connectively compatible with the electrical receptacles of the light panel assemblies; and
a plurality of connectors, each connector having a multi-lead electrical plug at each of opposing ends thereof and receivable in the electrical receptacles in the light panel assemblies.
2. The elongated hexagonal decorative light system according to claim 1 wherein the electrical receptacles at each end of the light panel assemblies are aligned parallel to a long axis of the light panel assembly.
3. The elongated hexagonal decorative light system according to claim 1 wherein the base further includes a visible orientation arrow corresponding to the arrangement orientation of the light emitting diodes on the printed circuit assembly of the light panel assembly to aid in the orientation of one light panel assembly to another like light panel assembly.
4. The elongated hexagonal decorative light system according to claim 1 wherein the prismatically shaped lens is translucent.
5. The elongated hexagonal decorative light system according to claim 4 wherein the prismatically shaped lens has a raised center and faceted sides, each faceted side corresponding to a side of the light panel assembly.
6. The elongated hexagonal decorative light system according to claim 1 wherein the controller further includes a plurality of microswitches electrically interconnected therewith for manual control inputs.
7. The elongated hexagonal decorative light system according to claim 6 wherein the microswitches are covered with a flexible membrane having legends embossed thereon for identification of the function of each microswitch.
8. The elongated hexagonal decorative light system according to claim 1 wherein the controller further includes circuitry and logic to be remotely responsive to wireless electronic inputs from a remote electronic device for controlling the plurality of light panel assemblies.
9. The elongated hexagonal decorative light system according to claim 1 wherein each of the connectors is directionally biased to permit flow of electrical signals in one direction only, at least one electrical plug bearing a visible legend identifying the directional bias of the connector.
10. The elongated hexagonal decorative light system according to claim 1 wherein the light panel assemblies of the system are identically responsive to electrical signals from the controller to display identical light patterns and motions concurrently.
11. The elongated hexagonal decorative light system according to claim 1 wherein the light panel assemblies of the system are responsive to electrical signals from the controller to display a progressive light pattern and motion across the plurality of the light panel assemblies.
12. The elongated hexagonal decorative light system according to claim 1 further including an octagonal mounting bracket, the mounting bracket having a magnet housed therein.
13. The elongated hexagonal decorative light system according to claim 12 wherein the light assembly base defines an octagonal aperture in a bottom surface thereof for receiving the octagonal mounting bracket.
14. The elongated hexagonal decorative light system according to claim 13 wherein the light assembly base further includes a magnetically sensitive plate mounted over the octagonal aperture in a manner that the magnetic force of the mounting bracket magnet retains the light panel assembly in a desired location and position, the light panel assembly being readily detachable and rotationally repositionable from the hexagonal mounting bracket by overcoming the magnetic force.
15. The elongated hexagonal decorative light system according to claim 1, wherein the connectors are electrically bidirectional.
16. The elongated hexagonal decorative light system according to claim 15 wherein the printed circuit assembly of the light panel assembly further includes circuitry and logic to determine which of the receptacles at each end of the light panel assembly is functioning as an electrical input and automatically electrically configures the remaining receptacles as electrical outputs.
17. An elongated hexagonal decorative light system comprising:
a plurality of light panel assemblies, each light panel assembly further comprising:
a base having an elongate hexagonal shaped outer periphery, the base defining two connector apertures at each end of the elongate base in a bottom of the base;
a printed circuit assembly mounted to the base and having a first plurality of white light emitting diodes populated thereon and a second plurality of colored light emitting diodes populated thereon and electronic circuitry for selectively illuminating between the white light emitting diodes and the colored light emitting diodes and circuitry and logic to illuminate the light emitting diodes thereon in a plurality of predetermined patterns and light motions;
a plurality of electrical receptacles, at least two receptacles positioned at each end of the printed circuit assembly, each electrical receptacle in registration with one of the connector apertures defined in the base at each end of the elongate base; and
a prismatically shaped translucent lens having a raised center and a facet corresponding with each side of the base and affixed to an upper surface of the base;
a controller having a base receiving an electrical power cord, the power cord electrically connected to a printed circuit assembly mounted on the base wherein the printed circuit assembly includes the circuitry and logic for controlling the plurality of light panel assemblies, a plurality of microswitches electrically interconnected therewith for manual control inputs, and further includes a signal and power cord extending therefrom and terminating with an electrical connector connectively compatible with the receptacles of the light panel assemblies;
an octagonal mounting bracket having a magnet embedded therein; and
a plurality of connector cables, each connector cable having a multi-lead cable segment terminated at each end with an electrical plug receivable in the electrical receptacles in the light panel assemblies.
18. The elongated hexagonal decorative light system according to claim 17 wherein the light assembly base defines an octagonal aperture in a bottom surface thereof for receiving the octagonal mounting bracket.
19. The elongated hexagonal decorative light system according to claim 18 wherein the light assembly base further includes a magnetically sensitive plate mounted over the octagonal aperture in a manner that the magnetic force of the mounting bracket magnet retains the light panel assembly in a desired location and position, the light panel assembly being readily detachable and rotationally repositionable from the octagonal mounting bracket by overcoming the magnetic force.

OFFICE ACTION:
EXAMINER'S AMENDMENT
Notice of Pre-AIA  or AIA  Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
An examiner’s amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
The application has been amended as follows:
In the title, after: “antibody”, please add:
-- and methods of using them for cancer treatment --.
In the Remarks submitted on 01/172025, Applicant requested that the status of the drawings submitted on 06/02/2022 should be indicated. Examiner positively affirm that the drawings were considered and accepted by the Examiner.
The Terminal Disclaimer over the U.S. Patent 11,352,430 submitted on 01/17/2025 was considered and approved by the Office.
The allowed claims are: 1-9.
Reasons for Allowance
The following is an examiner’s statement of reasons for allowance: Applicant submitted an amended Specification and a terminal disclaimed thus obviating the objections and rejections in the previous Office action.
Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee.  Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”

APPLICANT REBUTTAL: Remarks
Claims 1-9 are pending in the subject application. By this Amendment, Applicant has amended the application. It is respectfully submitted that no new matter is introduced by this amendment. Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 1-9 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.
The application was filed with Figures 1-14. The Office Action Summary page did not indicate that the drawings were accepted or objected to by the Examiner. Applicant respectfully requests that the Examiner consider the figures and indicate their status in the next communication.
The Examiner indicates that 35 U.S.C. § 1.12(a) requires the specification to be written in "full, clear, concise, and exact terms". The Office Action points to examples of some unclear, inexact or verbose terms used in the specification that were presented in the Certificate of Correction filed in the parent patent. Applicant notes that the Certificate of Correction that was filed (and subsequently issued) in U.S. Patent No. 11,352,430 identified errors that were introduced by the Patent Office when printing the patent. Regardless, Applicant has made amendments to the specification to correct typographical issues and grammatical issues. Entry of the amendments is respectfully requested.
Claims 1-9 are rejected under the judicially created doctrine of "obviousness-type" double patenting over claims 1-6 and 11-15 of U.S. Patent No. 11,352,430. Applicant respectfully asserts that the claims are not obvious over the cited patent. However, in order to expedite prosecution of the subject application, Applicant has submitted a Terminal Disclaimer with this Amendment which obviates this rejection. Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.
It should be understood that the amendments presented herein have been made
solely
to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicant's agreement with or acquiescence to the Examiner's position. Applicant expressly reserves the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.
In view of the foregoing remarks, Applicant believes that the currently pending claims are in condition for allowance, and such action is respectfully requested.
The Commissioner is hereby authorized to charge any fees under 37 C.F.R. § § 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.
Applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.
The undersigned hereby certifies that this correspondence is being transmitted by EFS-Web to the United States Patent and Trademark Office on January 17, 2025.
Respectfully submitted, /FRANK C. EISENSCHENK/Frank C. Eisenschenk, Ph.D.Patent Attorney


CITED REFERENCE SUMMARIES: Ref US11352430: Claims:
A humanized monoclonal anti-human-PD-1 antibody or an antigen-binding fragment thereof comprising: (a) a VH comprising or consisting of an amino acid sequence of SEQ ID NO: 21; and (b) a VL comprising or consisting of an amino acid sequence of SEQ ID NO: 24, wherein the antibody or antigen binding fragment thereof is an antagonist of the binding of human PD-L1 and/or PD-L2 to human PD-1.
The antibody or antigen-binding fragment of claim 1 , wherein it comprises: (a) a heavy chain comprising or consisting of an amino acid sequence of SEQ ID NO: 31, and (b) a light chain comprising or consisting of an amino acid sequence of SEQ ID NO: 34.
The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG1, IgG2, IgG3 or IgG4 heavy chain constant domain.
The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG1 heavy chain constant domain, optionally with a substitution or a combination of substitutions selected from the group consisting of T250Q/M428L; M252Y/S254T/T256E+H433K/N434F; E233P/L234V/L235A/G236A+A327G/A330S/P331S; E333A; S239D/A330L/I332E; P257I/Q311; K326W/E333S; S239D/I332E/G236A; N297A; L234A/L235A; N297A+M252Y/S254T/T256E; K322A and K444A, preferably selected from the group consisting of N297A optionally in combination with M252Y/S254T/T256E, and L234A/L235A.
The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG4 heavy chain constant domain, optionally with a substitution or a combination of substitutions selected from the group consisting of S228P; L234A/L235A, S228P+M252Y/S254T/T256E and K444A.
The antibody or antigen-binding fragment of claim 1 , which specifically binds to human PD-1 with a binding affinity constant (KD) for a human PD-1 equal or lower than 10 −7 M measured by surface plasmon resonance.
An isolated nucleic acid molecule or a group of isolated nucleic acid molecules encoding the antibody or antigen-binding fragment of claim 1 .
A vector comprising the isolated nucleic acid molecule or the group of isolated nucleic acid molecules of claim 7 .
A host cell comprising the isolated nucleic acid molecule and/or the group of isolated nucleic acid molecules of claim 7 and/or the vector comprising said nucleic acid molecule or group of nucleic acid molecules.
A method for producing antibody or antigen-binding fragment thereof comprising a step of culturing a host cell according to claim 9 and optionally a step of isolating the antibody or antigen-binding fragment.
A pharmaceutical composition comprising an antibody or an antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.
A method of treating cancer in a subject comprising administering an antibody or antigen binding fragment of claim 1 , or a composition comprising said antibody or antigen binding fragment and a pharmaceutically acceptable excipient, to a subject having cancer, said cancer being selected from the group consisting of malignant mesothelioma, colorectal cancer and hepatocellular carcinoma.
The method of claim 12 , wherein the cancer has tumor cells which are PD-L1 negative.
The method of claim 12 , wherein said antibody, antigen binding fragment or composition is administered in combination with radiotherapy or an additional therapeutic.
The method of claim 12 , wherein the subject to be treated is immunosuppressed, immunocompromised or immunodepressed.